More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Our Lady of the Lake Cancer Institute is celebrating after successfully completing a bone marrow transplant so rare it has ...

On this World Cancer Day, Chris Vogelsang, a cancer survivor from upstate New York, is celebrating his recovery thanks to a ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...

For four decades, Ohio State blood and bone marrow transplant innovation has improved cancer care with an increasing emphasis ...

Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

One hundred people have signed up to the stem cell register to see if they are a match for a man who has blood cancer.

Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients.

CARsgen’s first enrolled subject in the THANK-u Plus platform-based allogeneic CAR-T trial achieves sCR at week 4: Shanghai, China Tuesday, February 11, 2025, 18:00 Hrs [IST] CA ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...